ClinicalTrials.gg
CompletedNCT02868229Updated Jul 30, 2021Results posted

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

A Phase 1/2 interventional study of COR-001 and Placebo in Anemia, sponsored by Novo Nordisk A/S. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-30.

Sponsored by Novo Nordisk A/S · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
210th of 395
61 · median 72
Started
2016
with 24 others
Phase 1/2
19 of 464
4 open now
Registered
305th of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 210th largest by enrollment of the 395 interventional ones that give a count, is one of 25 that started in 2016, is one of 19 in phase 1/2, and was the 305th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of multiple doses of COR-001 or placebo

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 18 years at the time of signing of the ICF.
  2. The patient agrees to comply with the and reproduction restrictions of the study
  3. Receiving intravenous (IV) or subcutaneous (SC) erythropoietin stimulating agents (ESA) drugs continuously prescribed for a minimum of 8 weeks prior to Screening
  4. At least 2 ferritin values during Screening > 300 ng/mL
  5. At least 2 transferrin saturation (TSAT) values during Screening between 15% and 50% (inclusive)

Exclusion criteria

EXCLUSION CRITERIA:

  1. Use of systemic drugs during the Screening Period or anticipated use of such drugs any time during the study
  2. Clinical evidence or suspicion of active or smoldering infection by clinical or serologic criteria
  3. Actively treated or active
  4. Known or suspected occult or active bleeding
  5. Received a red blood cell or whole blood transfusion within 2 months prior to Screening or anticipated to receive a blood transfusion at any time during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    COR-001

    Drug: COR-001

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Characterization of Maximum Tolerated Dose (MTD)

    The MTD assessment was based on safety data. If more than 2 of 8 active participants in a cohort experience a Dose-Limiting Toxicities (DLT), the MTD was considered to have been exceeded. The DLT threshold was defined using a threshold of greater than or equal to (\>=) Grade 3 events, which includes severe: infusion-related reactions, cardiopulmonary infusion reactions, anaphylaxis, or hypersensitivity. DLTs are defined as follows: 1. Confirmed Grade 3 neutropenia and representing a decline of \> 25% from baseline 2. Serious adverse events (SAEs) of infection in the presence of confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia. 3. ≥ Grade 3 ALT (Alanine transaminase) or AST(Aspartate transaminase) 4. ≥ Grade 4 hematologic toxicity 5. ≥ Grade 3 non-hematologic toxicity

    Time frame: Weeks 0-24

  2. Change in High-sensitivity C-reactive Protein (hsCRP): Week 4

    Change from the baseline in hsCRP values to week 4 are presented.

    Time frame: From baseline (mean of screening and day 1) to week 4

  3. Change in Serum Amyloid A (SAA): Week 4

    Change from the baseline in serum amyloid A (SAA) values to week 4 are presented.

    Time frame: From baseline (mean of screening and day 1) to week 4

Secondary outcomes

  1. Number of Adverse Events of Special Interest

    Frequency of events of interest by treatment group and dose from baseline until the end of the safety follow-up period (week 24) were reported. Adverse events of special interest included severe infusion-related reactions, hypersensitivity reaction during study drug infusion, anaphylaxis and neutropenia events of grade 2 or higher (i.e., absolute neutrophil count \<1500/mm\^3 and decline by at least 25% from baseline).

    Time frame: Weeks 0-24

  2. Number of Treatment Emergent Adverse Events (TEAEs)

    An AE (adverse event) is any undesirable event or any untoward medical occurrence that occurs to a participant during the course of a study, or the protocol-defined time after study termination, whether or not that event is considered Study Drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of study. Number of TEAEs from baseline until the end of safety follow up (week 24) were presented.

    Time frame: Week 0-24

  3. Electrocardiogram (ECG)

    A summary of the overall ECG interpretation and clinical significance from baseline until the end of the safety follow up period (week 24) is presented and categorized as Normal, Abnormal clinically significant (CS), Abnormal non clinically significant (NCS) and Missing.

    Time frame: At baseline, week 6, week 12, week 18 and week 24

  4. Number of Participants Who Developed Anti-drug Antibodies (ADAs)

    Number of participants who developed ADAs from baseline until the end of the extended follow up period (week 35) were reported. Samples with detectable ADAs were classified as positive for ADAs. Samples without detectable ADAs were classified as negative for ADAs.

    Time frame: Weeks 0-35

  5. Number of Participants With ADA Titers

    Number of participants with ADA titers for ADA-positive samples from baseline to week 35 is presented.

    Time frame: Weeks 0-35

  6. Number of Participants With Neutralizing ADAs

    Number of participants with neutralizing ADAs from baseline to week 35 are presented.

    Time frame: From baseline (mean of screening and week 1) to week 35

  7. Change in Transferrin Saturation (TSAT): Week 4

    Change from baseline in TSAT to week 4 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 4

  8. Change in TSAT: Mean of Weeks 10-12

    Change from baseline in TSAT to the mean of weeks 10-12 is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  9. Change in Reticulocyte Hemoglobin (CHr): Week 4

    Change from baseline in CHr to week 4 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 4

  10. Change in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks

    Change from baseline in hs-CRP to the mean of 10-12 weeks is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  11. Change in SAA: Mean of Weeks 10-12

    Change from baseline in SAA to the mean of weeks 10-12 is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  12. Change in Serum Pre-albumin: Mean of 10-12 Weeks

    Change from baseline in serum pre-albumin to the mean of 10-12 weeks is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  13. Change in Albumin: Week 12

    Change from baseline in albumin to week 12 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 12

  14. Change in Erythropoietin Resistance Index (ERI): Week 4

    Change from baseline in ERI to week 4 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

    Time frame: From baseline (weekly mean of screening) to week 4

  15. Change in ERI: Mean of Weeks 8-12

    Change from baseline in ERI to the mean of weeks 8-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

    Time frame: From baseline (weekly mean of screening), week 8, week 12

  16. Change in ERI: Mean of Weeks 10-12

    Change from baseline in ERI to the mean of weeks 10-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

    Time frame: From baseline (weekly mean of screening), week 10, week 12

  17. Change in CHr: Mean of Weeks 10-12

    Change from baseline in CHr to the mean of weeks 10-12 is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  18. Change in Hemoglobin: Week 4

    Change from baseline in hemoglobin to week 4 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 4

  19. Change in Hemoglobin: Mean of Weeks 10-12

    Change from baseline in hemoglobin to weeks 10-12 is presented.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  20. Change in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose

    Change from baseline in hemoglobin to weeks 10-12, excluding hemoglobin values following a change in the total weekly ESA (erythropoiesis stimulating agent) dose is presented. A change is defined as the first time when the ESA weekly dose goes up by \>25% or down by \>25% relative to the previous week's dose.

    Time frame: From baseline (mean of screening and day 1), week 10, week 12

  21. Change in ERI: Week 12

    Change from baseline in ERI to week 12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

    Time frame: From baseline (weekly mean of screening) to week 12

  22. Change in ERI: Mean of Weeks 9-12

    Change from baseline in ERI to the mean of weeks 9-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

    Time frame: From baseline (weekly mean of screening), week 9, week 12

  23. Change in Hemoglobin: Week 12

    Change from baseline in hemoglobin to week 12 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 12

  24. Change in Hemoglobin: Week 24

    Change from baseline in hemoglobin to week 24 is presented.

    Time frame: From baseline (mean of screening and day 1) to week 24

  25. Change in Hemoglobin From Screening to Peak Hemoglobin: Week 4

    Change in hemoglobin from screening to peak hemoglobin at week 4 is presented.

    Time frame: From screening to week 4

  26. Basophils: Week 12

    The observed values of basophils at week 12 are presented.

    Time frame: At week 12

  27. Basophil: Week 24

    The observed values of basophils at week 24 are presented.

    Time frame: At week 24

  28. Basophils to Leukocytes Ratio: Week 12

    Basophils to leukocytes ratio at week 12 is presented.

    Time frame: At week 12

  29. Basophils to Leukocytes Ratio: Week 24

    Basophils to leukocytes ratio at week 24 is presented.

    Time frame: At week 24

  30. Eosinophils: Week 12

    The observed values of eosinophils at week 12 are presented.

    Time frame: At week 12

  31. Eosinophils: Week 24

    The observed values of eosinophils at week 24 are presented.

    Time frame: At week 24

  32. Eosinophils to Leukocytes Ratio: Week 12

    Eosinophils to leukocytes ratio at week 12 is presented.

    Time frame: At week 12

  33. Eosinophils to Leukocytes Ratio: Week 24

    The eosinophils to leukocytes ratio at week 24 is presented.

    Time frame: At week 24

  34. Erythrocyte Mean Corpuscular Hemoglobin: Week 12

    The observed values of erythrocyte mean corpuscular hemoglobin at week 12 are presented.

    Time frame: At week 12

  35. Erythrocyte Mean Corpuscular Hemoglobin: Week 24

    The observed values of erythrocyte mean corpuscular hemoglobin at week 24 are presented.

    Time frame: At week 24

  36. Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12

    The observed values of erythrocyte mean corpuscular HGB concentration at week 12 are presented.

    Time frame: At week 12

  37. Erythrocyte Mean Corpuscular HGB Concentration: Week 24

    The observed values of erythrocyte mean corpuscular HGB concentration at week 24 are presented.

    Time frame: At week 24

  38. Erythrocyte Mean Corpuscular Volume: Week 12

    The observed values of erythrocyte mean corpuscular volume at week 12 are presented.

    Time frame: At week 12

  39. Erythrocyte Mean Corpuscular Volume: Week 24

    The observed values of erythrocyte mean corpuscular volume at week 24 are presented.

    Time frame: At week 24

  40. Erythrocytes: Week 12

    The observed values of erythrocytes at week 12 are presented.

    Time frame: At week 12

  41. Erythrocytes: Week 24

    The observed values of erythrocytes at week 24 are presented.

    Time frame: At week 24

  42. Hematocrit: Week 12

    The observed values of hematocrit at week 12 are presented.

    Time frame: At week 12

  43. Hematocrit: Week 24

    The observed values of hematocrit at week 24 are presented.

    Time frame: At week 24

  44. Hemoglobin: Week 12

    The observed values of hemoglobin at week 12 are presented.

    Time frame: At week 12

  45. Hemoglobin: Week 24

    The observed values of hemoglobin at week 24 are presented.

    Time frame: At week 24

  46. Hypochromatic Red Cells Week 12

    The observed values of hypochromatic red cells at week 12 are presented.

    Time frame: At week 12

  47. Hypochromatic Red Cells: Week 24

    The observed values of hypochromatic red cells at week 24 are presented.

    Time frame: At week 24

  48. Leukocytes: Week 12

    The observed values of leukocytes at week 12 are presented.

    Time frame: At week 12

  49. Leukocytes: Week 24

    The observed values of leukocytes at week 24 are presented.

    Time frame: At week 24

  50. Lymphocytes: Week 12

    The observed values of lymphocytes at week 12 are presented.

    Time frame: At week 12

  51. Lymphocytes: Week 24

    The observed values of lymphocytes at week 24 are presented.

    Time frame: At week 24

  52. Lymphocytes to Leukocytes Ratio: Week 12

    Lymphocytes to leukocytes ratio at week 12 is presented.

    Time frame: At week 12

  53. Lymphocytes to Leukocytes Ratio at Week 24

    Lymphocytes to leukocytes ratio at week 24 is presented.

    Time frame: At week 24

  54. Monocytes: Week 12

    The observed values of monocytes at week 12 are presented.

    Time frame: At week 12

  55. Monocytes: Week 24

    The observed values of monocytes at week 24 are presented.

    Time frame: At week 24

  56. Monocytes to Leukocytes Ratio: Week 12

    Monocytes to leukocytes ratio at week 12 is presented.

    Time frame: At week 12

  57. Monocytes to Leukocytes Ratio: Week 24

    Monocytes to leukocytes ratio at week 24 is presented.

    Time frame: At week 24

  58. Neutrophils: Week 12

    The observed values of neutrophils at week 12 are presented.

    Time frame: At week 12

  59. Neutrophils: Week 24

    The observed values of neutrophils at week 24 are presented.

    Time frame: At week 24

  60. Neutrophils to Leukocytes Ratio: Week 12

    Neutrophils to leukocytes ratio at week 12 is presented.

    Time frame: At week 12

  61. Neutrophils to Leukocytes Ratio: Week 24

    Neutrophils to leukocytes ratio at week 24 is presented.

    Time frame: At week 24

  62. Platelets: Week 12

    The observed values of platelets at week 12 are presented.

    Time frame: At week 12

  63. Platelets: Week 24

    The observed values of platelets at week 24 are presented.

    Time frame: At week 24

  64. Reticulocytes to Erythrocytes Ratio: Week 12

    Reticulocytes to erythrocytes ratio at week 12 is presented.

    Time frame: At week 12

  65. Reticulocytes to Erythrocytes Ratio: Week 24

    Reticulocytes to erythrocytes ratio at week 24 is presented.

    Time frame: At week 24

  66. Alanine Aminotransferase: Week 12

    The observed values of alanine aminotransferase at week 12 are presented.

    Time frame: At week 12

  67. Alanine Aminotransferase: Week 24

    The observed values of alanine aminotransferase at week 24 are presented.

    Time frame: At week 24

  68. Albumin: Week 12

    The observed values of albumin at week 12 are presented.

    Time frame: At week 12

  69. Albumin: Week 24

    The observed values of albumin at week 24 are presented.

    Time frame: At week 24

  70. Alkaline Phosphatase: Week 12

    The observed values of alkaline phosphatase at week 12 are presented.

    Time frame: At week 12

  71. Alkaline Phosphatase: Week 24

    The observed values of alkaline phosphatase at week 24 are presented.

    Time frame: At week 24

  72. Aspartate Aminotransferase: Week 12

    The observed values of aspartate aminotransferase at week 12 are presented.

    Time frame: At week 12

  73. Aspartate Aminotransferase: Week 24

    The observed values of aspartate aminotransferase at week 24 are presented.

    Time frame: At week 24

  74. Bicarbonate: Week 12

    The observed values of bicarbonate at week 12 are presented.

    Time frame: At week 12

  75. Bicarbonate: Week 24

    The observed values of bicarbonate at week 24 are presented.

    Time frame: At week 24

  76. Bilirubin: Week 12

    The observed values of bilirubin at week 12 are presented.

    Time frame: At week 12

  77. Bilirubin: Week 24

    The observed values of bilirubin at week 24 are presented.

    Time frame: At week 24

  78. Calcium: Week 12

    The observed values of calcium at week 12 are presented.

    Time frame: At week 12

  79. Calcium: Week 24

    The observed values of calcium at week 24 are presented.

    Time frame: At week 24

  80. Chloride: Week 12

    The observed values of chloride at week 12 are presented.

    Time frame: At week 12

  81. Chloride: Week 24

    The observed values of chloride at week 24 are presented.

    Time frame: At week 24

  82. Cholesterol: Week 12

    The observed values of cholesterol at week 12 are presented.

    Time frame: At week 12

  83. Cholesterol: Week 24

    The observed values of cholesterol at week 24 are presented.

    Time frame: At week 24

  84. Creatinine: Week 12

    The observed values of creatinine at week 12 are presented.

    Time frame: At week 12

  85. Creatinine: Week 24

    The observed values of creatinine at week 24 are presented.

    Time frame: At week 24

  86. Direct Bilirubin: Week 12

    The observed values of direct bilirubin at week 12 are presented.

    Time frame: At week 12

  87. Direct Bilirubin: Week 24

    The observed values of direct bilirubin at week 24 are presented.

    Time frame: At week 24

  88. Glucose: Week 12

    The observed values of glucose at week 12 are presented.

    Time frame: At week 12

  89. Glucose: Week 24

    The observed values of glucose at week 24 are presented.

    Time frame: At week 24

  90. High-density Lipoprotein (HDL) Cholesterol: Week 12

    The observed values of HDL cholesterol at week 12 are presented.

    Time frame: At week 12

  91. HDL Cholesterol: Week 24

    The observed values of HDL cholesterol at week 24 are presented.

    Time frame: At week 24

  92. Hepcidin-25: Week 12

    The observed values of hepcidin-25 at week 12 are presented.

    Time frame: At week 12

  93. Hepcidin-25: Week 24

    The observed values of hepcidin-25 at week 24 are presented.

    Time frame: At week 24

  94. Low-density Lipoproteins (LDL) Cholesterol: Week 12

    The observed values of LDL cholesterol at week 12 are presented.

    Time frame: At week 12

  95. LDL Cholesterol: Week 24

    The observed values of LDL cholesterol at week 24 are presented.

    Time frame: At week 24

  96. Lipoprotein-a: Week 12

    The observed values of lipoprotein-a at week 12 are presented.

    Time frame: At week 12

  97. Lipoprotein-a: Week 24

    The observed values of lipoprotein-a at week 24 are presented.

    Time frame: At week 24

  98. Phosphate: Week 12

    The observed values of phosphate at week 12 are presented.

    Time frame: At week 12

  99. Phosphate: Week 24

    The observed values of phosphate at week 24 are presented.

    Time frame: At week 24

  100. Potassium: Week 12

    The observed values of potassium at week 12 are presented.

    Time frame: At week 12

  101. Potassium: Week 24

    The observed values of potassium at week 24 are presented.

    Time frame: At week 24

  102. Sodium: Week 12

    The observed values of sodium at week 12 are presented.

    Time frame: At week 12

  103. Sodium: Week 24

    The observed values of sodium at week 24 are presented.

    Time frame: At week 24

  104. Triglycerides: Week 12

    The observed values of triglyceride at week 12 are presented.

    Time frame: At week 12

  105. Triglycerides: Week 24

    The observed values of triglycerides at week 24 are presented.

    Time frame: At week 24

  106. Urea Nitrogen: Week 12

    The observed values of urea nitrogen at week 12 are presented.

    Time frame: At week 12

  107. Urea Nitrogen: Week 24

    The observed values of urea nitrogen at week 24 are presented.

    Time frame: At week 24

  108. Pre-dialysis Body Mass Index (BMI): Week 12

    Pre-dialysis BMI values at week 12 are presented.

    Time frame: At week 12

  109. Pre-infusion BMI: Week 11

    Pre-infusion BMI values at week 11 are presented.

    Time frame: At week 11

  110. Pre-dialysis Diastolic Blood Pressure: Week 12

    Pre-dialysis diastolic blood pressure values at week 12 are presented.

    Time frame: At week 12

  111. Pre-dialysis Diastolic Blood Pressure: Week 24

    Pre-dialysis diastolic blood pressure values at week 24 are presented.

    Time frame: At week 24

  112. Pre-infusion Diastolic Blood Pressure: Week 11

    Pre-infusion diastolic blood pressure values at week 11 are presented.

    Time frame: At week 11

  113. Pre-dialysis Heart Rate: Week 12

    Pre-dialysis heart rate values at week 12 are presented.

    Time frame: At week 12

  114. Pre-dialysis Heart Rate: Week 24

    Pre-dialysis heart rate values at week 24 are presented.

    Time frame: At week 24

  115. Pre-infusion Heart Rate: Week 11

    Pre-infusion heart rate values at week 11 are presented.

    Time frame: At week 11

  116. Pre-dialysis Respiration Rate: Week 12

    Pre-dialysis respiration rate values at week 12 are presented.

    Time frame: At week 12

  117. Pre-dialysis Respiration Rate: Week 24

    Pre-dialysis respiration rate values at week 24 are presented.

    Time frame: At week 24

  118. Pre-infusion Respiration Rate: Week 11

    Pre-infusion respiration rate values at week 11 are presented.

    Time frame: At week 11

  119. Pre-dialysis Systolic Blood Pressure: Week 12

    Pre-dialysis values of systolic blood pressure at week 12 are presented.

    Time frame: At week 12

  120. Pre-dialysis Systolic Blood Pressure: Week 24

    Pre-dialysis values of systolic blood pressure at week 24 are presented.

    Time frame: At week 24

  121. Pre-infusion Systolic Blood Pressure: Week 11

    Pre-infusion systolic blood pressure values at week 11 are presented.

    Time frame: At week 11

  122. Pre-dialysis Weight: Week 12

    Pre-dialysis weight values at week 12 are presented.

    Time frame: At week 12

  123. Pre-infusion Weight: Week 11

    Pre-infusion weight values at week 11 are presented.

    Time frame: At week 11

  124. Pre-dialysis Temperature: Week 12

    Pre-dialysis temperature values at week 12 are presented.

    Time frame: At week 12

  125. Pre-dialysis Temperature: Week 24

    Pre-dialysis temperature values at week 24 are presented.

    Time frame: At week 24

  126. Pre-infusion Temperature: Week 11

    Pre-infusion temperature values at week 11 are presented.

    Time frame: At week 11

  127. Area Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-001

    Area under the serum concentration time curve from time 0 to infinity (AUC 0-α) of COR-001 is presented.

    Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).

  128. Elimination Half-life in the Initial Phase (t 1/2,α)

    Elimination half-life in the initial phase (t 1/2,α) is presented from week 0 to week 35.

    Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).

  129. Elimination Half-life in the Terminal Phase (t 1/2, z)

    Elimination half-life in the terminal phase(t 1/2, z) is presented from week 0 to week 35.

    Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).

  130. Maximum Serum Concentration (Cmax)

    Maximum serum concentration (Cmax) of COR-001 from week 0 to week 35 is presented.

    Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).

  131. Impact of ADAs on Pharmacokinetics

    Presence of ADA was a covariate for pharmacokinetics (PK) affecting V1 (volume of distribution for the central compartment). Impact of ADAs on V1 from baseline to week 35 is presented. In the below table, result presented is the bootstrap parameter estimate of the effect of ADA on V1 for a PK model that includes data for all arms combined.

    Time frame: Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).

07

Results

Posted Jul 30, 2021

Participant flow

The trial was conducted at 13 sites in the United States.

Participant flow — Overall Study
MilestonePlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Started12161617
Intent to treat (itt) population12161617
Pharmacodynamic (pd) population12161312
Pharmacokinetic (pk) population12161617
Safety analysis population12161617
Maximum tolerated dose (mtd) population12161616
Completed11161512
Not completed1015
Withdrew: Adverse event1001
Withdrew: Death0011
Withdrew: Missed dose0003

Outcome measures

PrimaryCharacterization of Maximum Tolerated Dose (MTD)

The MTD assessment was based on safety data. If more than 2 of 8 active participants in a cohort experience a Dose-Limiting Toxicities (DLT), the MTD was considered to have been exceeded. The DLT threshold was defined using a threshold of greater than or equal to (\>=) Grade 3 events, which includes severe: infusion-related reactions, cardiopulmonary infusion reactions, anaphylaxis, or hypersensitivity. DLTs are defined as follows: 1. Confirmed Grade 3 neutropenia and representing a decline of \> 25% from baseline 2. Serious adverse events (SAEs) of infection in the presence of confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia. 3. ≥ Grade 3 ALT (Alanine transaminase) or AST(Aspartate transaminase) 4. ≥ Grade 4 hematologic toxicity 5. ≥ Grade 3 non-hematologic toxicity

Time frame:
Weeks 0-24
Reported as:
Number · Events
Characterization of Maximum Tolerated Dose (MTD)
EventsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Infection SAEs with confirmed Grade 2 or higher new onset lymphopenia or new onset neutropenia.0000
>= Grade 3 ALT or AST0000
>= Grade 4 hematologic toxicity0000
>= Grade 3 non-hematologic toxicity0000
Confirmed Grade 3 neutropenia and representing a decline of > 25% from baseline0000
PrimaryChange in High-sensitivity C-reactive Protein (hsCRP): Week 4

Change from the baseline in hsCRP values to week 4 are presented.

Time frame:
From baseline (mean of screening and day 1) to week 4
Reported as:
Mean · Milligrams per liter (mg/L)
Change in High-sensitivity C-reactive Protein (hsCRP): Week 4
Milligrams per liter (mg/L)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in High-sensitivity C-reactive Protein (hsCRP): Week 40.373 ± 3.765-10.383 ± 10.395-11.981 ± 8.232-14.561 ± 11.836
Statistical analysis
  • Placebo vs COR-001 2 mg · ANCOVA · p = 0.002 · Differences of ls means: -5.666 · 95% CI -9.082 to -2.250
  • Placebo vs COR-001 6 mg · ANCOVA · p = <0.001 · Differences of ls means: -6.913 · 95% CI -10.613 to -3.214
  • Placebo vs COR-001 20 mg · ANCOVA · p = <0.001 · Differences of ls means: -9.591 · 95% CI -13.217 to -5.965
PrimaryChange in Serum Amyloid A (SAA): Week 4

Change from the baseline in serum amyloid A (SAA) values to week 4 are presented.

Time frame:
From baseline (mean of screening and day 1) to week 4
Reported as:
Mean · mg/L
Change in Serum Amyloid A (SAA): Week 4
mg/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Serum Amyloid A (SAA): Week 4-3.733 ± 6.955-22.056 ± 37.914-9.878 ± 6.687-31.910 ± 41.502
SecondaryNumber of Adverse Events of Special Interest

Frequency of events of interest by treatment group and dose from baseline until the end of the safety follow-up period (week 24) were reported. Adverse events of special interest included severe infusion-related reactions, hypersensitivity reaction during study drug infusion, anaphylaxis and neutropenia events of grade 2 or higher (i.e., absolute neutrophil count \<1500/mm\^3 and decline by at least 25% from baseline).

Time frame:
Weeks 0-24
Reported as:
Number · Events
Number of Adverse Events of Special Interest
EventsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Number of Adverse Events of Special Interest0000
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An AE (adverse event) is any undesirable event or any untoward medical occurrence that occurs to a participant during the course of a study, or the protocol-defined time after study termination, whether or not that event is considered Study Drug-related. A TEAE was defined as an AE that initiated or worsened on or after the date of first dose of study drug up to the end of study. Number of TEAEs from baseline until the end of safety follow up (week 24) were presented.

Time frame:
Week 0-24
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Number of Treatment Emergent Adverse Events (TEAEs)33518366
SecondaryElectrocardiogram (ECG)

A summary of the overall ECG interpretation and clinical significance from baseline until the end of the safety follow up period (week 24) is presented and categorized as Normal, Abnormal clinically significant (CS), Abnormal non clinically significant (NCS) and Missing.

Time frame:
At baseline, week 6, week 12, week 18 and week 24
Reported as:
Count of participants · Participants
Electrocardiogram (ECG)
ParticipantsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Baseline — Normal5747
Baseline — Abnormal, clinically significant (CS)1111
Baseline — Abnormal, non clinically significant (NCS)68119
Baseline — Missing0000
Week 6 — Normal6344
Week 6 — Abnormal, clinically significant (CS)1110
Week 6 — Abnormal, non clinically significant (NCS)512810
Week 6 — Missing0033
Week 12 — Normal4533
Week 12 — Abnormal, clinically significant (CS)1121
Week 12 — Abnormal, non clinically significant (NCS)7101011
Week 12 — Missing0012
Week 18 — Normal7442
Week 18 — Abnormal, clinically significant (CS)1100
Week 18 — Abnormal, non clinically significant (NCS)41189
Week 18 — Missing0046
Week 24 — Normal3550
Week 24 — Abnormal, clinically significant (CS)1101
Week 24 — Abnormal, non clinically significant (NCS)710810
Week 24 — Missing1036
SecondaryNumber of Participants Who Developed Anti-drug Antibodies (ADAs)

Number of participants who developed ADAs from baseline until the end of the extended follow up period (week 35) were reported. Samples with detectable ADAs were classified as positive for ADAs. Samples without detectable ADAs were classified as negative for ADAs.

Time frame:
Weeks 0-35
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-drug Antibodies (ADAs)
ParticipantsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Positive2214
Negative10141513
SecondaryNumber of Participants With ADA Titers

Number of participants with ADA titers for ADA-positive samples from baseline to week 35 is presented.

Time frame:
Weeks 0-35
Reported as:
Count of participants · Participants
Number of Participants With ADA Titers
ParticipantsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Number of Participants With ADA Titers2214
SecondaryNumber of Participants With Neutralizing ADAs

Number of participants with neutralizing ADAs from baseline to week 35 are presented.

Time frame:
From baseline (mean of screening and week 1) to week 35
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing ADAs
ParticipantsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Number of Participants With Neutralizing ADAs0000
SecondaryChange in Transferrin Saturation (TSAT): Week 4

Change from baseline in TSAT to week 4 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 4
Reported as:
Mean · Percentage of TSAT
Change in Transferrin Saturation (TSAT): Week 4
Percentage of TSATPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Transferrin Saturation (TSAT): Week 40.467 ± 6.7335.622 ± 12.9421.806 ± 11.19715.778 ± 12.384
SecondaryChange in TSAT: Mean of Weeks 10-12

Change from baseline in TSAT to the mean of weeks 10-12 is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · Percentage of TSAT
Change in TSAT: Mean of Weeks 10-12
Percentage of TSATPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in TSAT: Mean of Weeks 10-122.278 ± 8.0936.417 ± 7.1579.167 ± 8.5699.028 ± 6.121
SecondaryChange in Reticulocyte Hemoglobin (CHr): Week 4

Change from baseline in CHr to week 4 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 4
Reported as:
Mean · Picograms (pg)
Change in Reticulocyte Hemoglobin (CHr): Week 4
Picograms (pg)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Reticulocyte Hemoglobin (CHr): Week 4-0.265 ± 1.2161.197 ± 1.1831.188 ± 1.0900.286 ± 2.265
SecondaryChange in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks

Change from baseline in hs-CRP to the mean of 10-12 weeks is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · mg/L
Change in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks
mg/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in High Sensitivity C-reactive Protein (Hs-CRP): Mean of 10-12 Weeks-0.021 ± 0.293-0.534 ± 0.439-0.916 ± 0.337-1.462 ± 0.554
SecondaryChange in SAA: Mean of Weeks 10-12

Change from baseline in SAA to the mean of weeks 10-12 is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · mg/L
Change in SAA: Mean of Weeks 10-12
mg/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in SAA: Mean of Weeks 10-12-1.262 ± 19.056-24.323 ± 41.375-8.688 ± 6.665-30.324 ± 37.812
SecondaryChange in Serum Pre-albumin: Mean of 10-12 Weeks

Change from baseline in serum pre-albumin to the mean of 10-12 weeks is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · Milligrams per decilitre (mg/dL)
Change in Serum Pre-albumin: Mean of 10-12 Weeks
Milligrams per decilitre (mg/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Serum Pre-albumin: Mean of 10-12 Weeks0.273 ± 5.7166.032 ± 6.9898.571 ± 5.36211.170 ± 4.983
SecondaryChange in Albumin: Week 12

Change from baseline in albumin to week 12 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 12
Reported as:
Mean · Grams per decilitre (g/dL)
Change in Albumin: Week 12
Grams per decilitre (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Albumin: Week 120.042 ± 0.2880.122 ± 0.2120.192 ± 0.1510.336 ± 0.192
SecondaryChange in Erythropoietin Resistance Index (ERI): Week 4

Change from baseline in ERI to week 4 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

Time frame:
From baseline (weekly mean of screening) to week 4
Reported as:
Mean · (Unit/kg/week) per (g/dL)
Change in Erythropoietin Resistance Index (ERI): Week 4
(Unit/kg/week) per (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Erythropoietin Resistance Index (ERI): Week 4-1.444 ± 3.590-0.975 ± 1.716-3.175 ± 4.761-4.211 ± 5.785
SecondaryChange in ERI: Mean of Weeks 8-12

Change from baseline in ERI to the mean of weeks 8-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

Time frame:
From baseline (weekly mean of screening), week 8, week 12
Reported as:
Mean · (Units/kg/week) per (g/dL)
Change in ERI: Mean of Weeks 8-12
(Units/kg/week) per (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in ERI: Mean of Weeks 8-12-2.714 ± 10.546-5.689 ± 7.824-7.842 ± 8.231-8.787 ± 5.952
SecondaryChange in ERI: Mean of Weeks 10-12

Change from baseline in ERI to the mean of weeks 10-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

Time frame:
From baseline (weekly mean of screening), week 10, week 12
Reported as:
Mean · (Units/kg/week) per (g/dL)
Change in ERI: Mean of Weeks 10-12
(Units/kg/week) per (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in ERI: Mean of Weeks 10-12-2.112 ± 11.476-6.477 ± 8.756-8.272 ± 8.770-8.690 ± 6.005
SecondaryChange in CHr: Mean of Weeks 10-12

Change from baseline in CHr to the mean of weeks 10-12 is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · pg
Change in CHr: Mean of Weeks 10-12
pgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in CHr: Mean of Weeks 10-12-0.035 ± 1.2640.859 ± 1.0981.271 ± 1.2641.143 ± 1.635
SecondaryChange in Hemoglobin: Week 4

Change from baseline in hemoglobin to week 4 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 4
Reported as:
Mean · g/dL
Change in Hemoglobin: Week 4
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin: Week 4-0.043 ± 1.4160.473 ± 0.7510.805 ± 0.9570.973 ± 0.720
SecondaryChange in Hemoglobin: Mean of Weeks 10-12

Change from baseline in hemoglobin to weeks 10-12 is presented.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · g/dL
Change in Hemoglobin: Mean of Weeks 10-12
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin: Mean of Weeks 10-12-0.107 ± 1.7560.848 ± 1.1560.963 ± 1.1310.772 ± 1.236
SecondaryChange in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose

Change from baseline in hemoglobin to weeks 10-12, excluding hemoglobin values following a change in the total weekly ESA (erythropoiesis stimulating agent) dose is presented. A change is defined as the first time when the ESA weekly dose goes up by \>25% or down by \>25% relative to the previous week's dose.

Time frame:
From baseline (mean of screening and day 1), week 10, week 12
Reported as:
Mean · g/dL
Change in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin: Mean of Weeks 10-12, Excluding Hemoglobin Values Following a Change in the Total Weekly ESA Dose0.352 ± 1.2250.228 ± 0.5060.627 ± 0.9880.567 ± 1.226
SecondaryChange in ERI: Week 12

Change from baseline in ERI to week 12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

Time frame:
From baseline (weekly mean of screening) to week 12
Reported as:
Mean · (Units/kg/week) per (g/dL)
Change in ERI: Week 12
(Units/kg/week) per (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in ERI: Week 12-3.229 ± 12.084-6.381 ± 8.956-8.835 ± 8.785-8.690 ± 6.356
SecondaryChange in ERI: Mean of Weeks 9-12

Change from baseline in ERI to the mean of weeks 9-12 is presented. ERI is defined as the epoetin alfa-equivalent dose (weight-based per week in U/kg) divided by the serum hemoglobin (in g/dL).

Time frame:
From baseline (weekly mean of screening), week 9, week 12
Reported as:
Mean · (Units/kg/week) per (g/dL)
Change in ERI: Mean of Weeks 9-12
(Units/kg/week) per (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in ERI: Mean of Weeks 9-12-2.320 ± 11.392-6.338 ± 8.870-8.293 ± 8.780-8.756 ± 5.949
SecondaryChange in Hemoglobin: Week 12

Change from baseline in hemoglobin to week 12 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 12
Reported as:
Mean · g/dL
Change in Hemoglobin: Week 12
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin: Week 120.130 ± 1.2400.502 ± 1.0290.806 ± 1.2340.755 ± 1.379
SecondaryChange in Hemoglobin: Week 24

Change from baseline in hemoglobin to week 24 is presented.

Time frame:
From baseline (mean of screening and day 1) to week 24
Reported as:
Mean · g/dL
Change in Hemoglobin: Week 24
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin: Week 24-0.803 ± 1.9290.154 ± 1.083-0.267 ± 0.826-0.079 ± 0.703
SecondaryChange in Hemoglobin From Screening to Peak Hemoglobin: Week 4

Change in hemoglobin from screening to peak hemoglobin at week 4 is presented.

Time frame:
From screening to week 4
Reported as:
Mean · g/dL
Change in Hemoglobin From Screening to Peak Hemoglobin: Week 4
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Change in Hemoglobin From Screening to Peak Hemoglobin: Week 4-0.043 ± 1.4160.473 ± 0.7510.805 ± 0.9570.973 ± 0.720
SecondaryBasophils: Week 12

The observed values of basophils at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells per microliter(10^3 cells/uL)
Basophils: Week 12
10^3 cells per microliter(10^3 cells/uL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Basophils: Week 120.03 ± 0.0480.02 ± 0.0410.04 ± 0.0510.03 ± 0.062
SecondaryBasophil: Week 24

The observed values of basophils at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Basophil: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Basophil: Week 240.05 ± 0.0520.04 ± 0.0620.08 ± 0.0830.02 ± 0.042
SecondaryBasophils to Leukocytes Ratio: Week 12

Basophils to leukocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of basophils to leukocytes
Basophils to Leukocytes Ratio: Week 12
Ratio of basophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Basophils to Leukocytes Ratio: Week 120.65 ± 0.4580.45 ± 0.5530.95 ± 0.4470.87 ± 0.954
SecondaryBasophils to Leukocytes Ratio: Week 24

Basophils to leukocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of basophils to leukocytes
Basophils to Leukocytes Ratio: Week 24
Ratio of basophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Basophils to Leukocytes Ratio: Week 240.62 ± 0.4580.83 ± 0.7221.29 ± 1.2960.57 ± 0.521
SecondaryEosinophils: Week 12

The observed values of eosinophils at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Eosinophils: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Eosinophils: Week 120.16 ± 0.0700.35 ± 0.2470.18 ± 0.0800.65 ± 1.706
SecondaryEosinophils: Week 24

The observed values of eosinophils at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Eosinophils: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Eosinophils: Week 240.19 ± 0.0830.29 ± 0.1890.30 ± 0.3360.36 ± 0.683
SecondaryEosinophils to Leukocytes Ratio: Week 12

Eosinophils to leukocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of eosinophils to leukocytes
Eosinophils to Leukocytes Ratio: Week 12
Ratio of eosinophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Eosinophils to Leukocytes Ratio: Week 123.39 ± 1.4335.56 ± 3.2344.14 ± 1.6697.32 ± 10.738
SecondaryEosinophils to Leukocytes Ratio: Week 24

The eosinophils to leukocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of eosinophils to leukocytes
Eosinophils to Leukocytes Ratio: Week 24
Ratio of eosinophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Eosinophils to Leukocytes Ratio: Week 243.49 ± 1.6114.44 ± 2.2875.32 ± 4.7483.98 ± 3.985
SecondaryErythrocyte Mean Corpuscular Hemoglobin: Week 12

The observed values of erythrocyte mean corpuscular hemoglobin at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · pg
Erythrocyte Mean Corpuscular Hemoglobin: Week 12
pgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular Hemoglobin: Week 1230.2 ± 1.4831.3 ± 2.6630.8 ± 2.1531.2 ± 2.48
SecondaryErythrocyte Mean Corpuscular Hemoglobin: Week 24

The observed values of erythrocyte mean corpuscular hemoglobin at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · pg
Erythrocyte Mean Corpuscular Hemoglobin: Week 24
pgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular Hemoglobin: Week 2429.5 ± 2.5431.0 ± 2.8030.6 ± 2.4029.6 ± 2.46
SecondaryErythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12

The observed values of erythrocyte mean corpuscular HGB concentration at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Grams per deciliter (g/dL)
Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 12
Grams per deciliter (g/dL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular Hemoglobin (HGB) Concentration: Week 1230.86 ± 1.33231.41 ± 1.43829.75 ± 1.56331.23 ± 0.978
SecondaryErythrocyte Mean Corpuscular HGB Concentration: Week 24

The observed values of erythrocyte mean corpuscular HGB concentration at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · g/dL
Erythrocyte Mean Corpuscular HGB Concentration: Week 24
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular HGB Concentration: Week 2430.78 ± 1.57231.04 ± 1.30729.52 ± 1.79930.28 ± 1.297
SecondaryErythrocyte Mean Corpuscular Volume: Week 12

The observed values of erythrocyte mean corpuscular volume at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · femtoliters (fL)
Erythrocyte Mean Corpuscular Volume: Week 12
femtoliters (fL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular Volume: Week 1298.16 ± 4.32899.35 ± 6.923103.49 ± 9.15399.97 ± 8.089
SecondaryErythrocyte Mean Corpuscular Volume: Week 24

The observed values of erythrocyte mean corpuscular volume at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · fL
Erythrocyte Mean Corpuscular Volume: Week 24
fLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocyte Mean Corpuscular Volume: Week 2495.70 ± 6.09699.69 ± 6.859103.53 ± 8.55097.76 ± 6.983
SecondaryErythrocytes: Week 12

The observed values of erythrocytes at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^6 cells per microliter(10^6 cells/uL)
Erythrocytes: Week 12
10^6 cells per microliter(10^6 cells/uL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocytes: Week 123.464 ± 0.3023.348 ± 0.4383.459 ± 0.4113.370 ± 0.345
SecondaryErythrocytes: Week 24

The observed values of erythrocytes at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^6 cells/uL
Erythrocytes: Week 24
10^6 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Erythrocytes: Week 243.312 ± 0.4803.256 ± 0.3473.111 ± 0.3883.365 ± 0.513
SecondaryHematocrit: Week 12

The observed values of hematocrit at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Percentage of Hematocrit
Hematocrit: Week 12
Percentage of HematocritPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hematocrit: Week 1234.0 ± 3.4333.1 ± 3.3135.6 ± 3.1333.7 ± 4.24
SecondaryHematocrit: Week 24

The observed values of hematocrit at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · Percentage of Hematocrit
Hematocrit: Week 24
Percentage of HematocritPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hematocrit: Week 2431.5 ± 3.7232.4 ± 2.7832.2 ± 4.1132.8 ± 3.58
SecondaryHemoglobin: Week 12

The observed values of hemoglobin at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · g/dL
Hemoglobin: Week 12
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hemoglobin: Week 1210.51 ± 1.19010.37 ± 0.92810.56 ± 1.01810.53 ± 1.360
SecondaryHemoglobin: Week 24

The observed values of hemoglobin at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · g/dL
Hemoglobin: Week 24
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hemoglobin: Week 249.68 ± 1.05710.06 ± 1.0319.47 ± 1.1359.87 ± 1.215
SecondaryHypochromatic Red Cells Week 12

The observed values of hypochromatic red cells at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Percentage of Hypochromatic red cells
Hypochromatic Red Cells Week 12
Percentage of Hypochromatic red cellsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hypochromatic Red Cells Week 1213.65 ± 15.01512.09 ± 11.19123.65 ± 22.21411.99 ± 14.657
SecondaryHypochromatic Red Cells: Week 24

The observed values of hypochromatic red cells at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · Percentage of Hypochromatic red cells
Hypochromatic Red Cells: Week 24
Percentage of Hypochromatic red cellsPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hypochromatic Red Cells: Week 2411.88 ± 10.81911.60 ± 11.89532.02 ± 25.22415.44 ± 13.415
SecondaryLeukocytes: Week 12

The observed values of leukocytes at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Leukocytes: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Leukocytes: Week 125.23 ± 1.7185.84 ± 1.8374.68 ± 1.0695.25 ± 3.004
SecondaryLeukocytes: Week 24

The observed values of leukocytes at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Leukocytes: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Leukocytes: Week 245.52 ± 2.1976.06 ± 1.6895.52 ± 1.1686.13 ± 3.414
SecondaryLymphocytes: Week 12

The observed values of lymphocytes at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Lymphocytes: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lymphocytes: Week 121.10 ± 0.3061.45 ± 0.6781.11 ± 0.2501.18 ± 0.388
SecondaryLymphocytes: Week 24

The observed values of lymphocytes at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Lymphocytes: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lymphocytes: Week 241.10 ± 0.4521.26 ± 0.4961.08 ± 0.2671.23 ± 0.523
SecondaryLymphocytes to Leukocytes Ratio: Week 12

Lymphocytes to leukocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of lymphocytes to leukocytes
Lymphocytes to Leukocytes Ratio: Week 12
Ratio of lymphocytes to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lymphocytes to Leukocytes Ratio: Week 1222.86 ± 9.13925.09 ± 9.61124.15 ± 5.77424.81 ± 7.341
SecondaryLymphocytes to Leukocytes Ratio at Week 24

Lymphocytes to leukocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of lymphocytes to leukocytes
Lymphocytes to Leukocytes Ratio at Week 24
Ratio of lymphocytes to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lymphocytes to Leukocytes Ratio at Week 2421.47 ± 11.35021.24 ± 7.19520.63 ± 6.99721.71 ± 7.633
SecondaryMonocytes: Week 12

The observed values of monocytes at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Monocytes: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Monocytes: Week 120.26 ± 0.1510.29 ± 0.1710.25 ± 0.1020.31 ± 0.119
SecondaryMonocytes: Week 24

The observed values of monocytes at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Monocytes: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Monocytes: Week 240.40 ± 0.1840.39 ± 0.2000.31 ± 0.1380.30 ± 0.067
SecondaryMonocytes to Leukocytes Ratio: Week 12

Monocytes to leukocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of monocytes to leukocytes
Monocytes to Leukocytes Ratio: Week 12
Ratio of monocytes to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Monocytes to Leukocytes Ratio: Week 125.61 ± 2.8715.42 ± 2.6495.15 ± 1.6526.21 ± 2.230
SecondaryMonocytes to Leukocytes Ratio: Week 24

Monocytes to leukocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of monocytes to leukocytes
Monocytes to Leukocytes Ratio: Week 24
Ratio of monocytes to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Monocytes to Leukocytes Ratio: Week 247.04 ± 2.3696.29 ± 2.2815.49 ± 1.7705.77 ± 2.396
SecondaryNeutrophils: Week 12

The observed values of neutrophils at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Neutrophils: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Neutrophils: Week 123.68 ± 1.6113.70 ± 1.4553.09 ± 0.9213.09 ± 1.354
SecondaryNeutrophils: Week 24

The observed values of neutrophils at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Neutrophils: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Neutrophils: Week 243.82 ± 1.7954.08 ± 1.2523.71 ± 1.0474.25 ± 2.507
SecondaryNeutrophils to Leukocytes Ratio: Week 12

Neutrophils to leukocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of neutrophils to leukocytes
Neutrophils to Leukocytes Ratio: Week 12
Ratio of neutrophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Neutrophils to Leukocytes Ratio: Week 1267.29 ± 11.70762.41 ± 10.14865.61 ± 7.44760.79 ± 9.656
SecondaryNeutrophils to Leukocytes Ratio: Week 24

Neutrophils to leukocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of neutrophils to leukocytes
Neutrophils to Leukocytes Ratio: Week 24
Ratio of neutrophils to leukocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Neutrophils to Leukocytes Ratio: Week 2467.37 ± 13.39667.21 ± 8.77167.31 ± 8.29367.94 ± 8.750
SecondaryPlatelets: Week 12

The observed values of platelets at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · 10^3 cells/uL
Platelets: Week 12
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Platelets: Week 12169.8 ± 68.37168.3 ± 38.62129.4 ± 42.26143.8 ± 48.68
SecondaryPlatelets: Week 24

The observed values of platelets at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · 10^3 cells/uL
Platelets: Week 24
10^3 cells/uLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Platelets: Week 24180.2 ± 62.44203.1 ± 57.78151.6 ± 41.75160.1 ± 55.67
SecondaryReticulocytes to Erythrocytes Ratio: Week 12

Reticulocytes to erythrocytes ratio at week 12 is presented.

Time frame:
At week 12
Reported as:
Mean · Ratio of reticulocytes to erythrocytes
Reticulocytes to Erythrocytes Ratio: Week 12
Ratio of reticulocytes to erythrocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Reticulocytes to Erythrocytes Ratio: Week 121.92 ± 0.8521.68 ± 0.7572.14 ± 1.2032.32 ± 1.537
SecondaryReticulocytes to Erythrocytes Ratio: Week 24

Reticulocytes to erythrocytes ratio at week 24 is presented.

Time frame:
At week 24
Reported as:
Mean · Ratio of reticulocytes to erythrocytes
Reticulocytes to Erythrocytes Ratio: Week 24
Ratio of reticulocytes to erythrocytesPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Reticulocytes to Erythrocytes Ratio: Week 241.95 ± 0.8721.96 ± 0.6691.84 ± 0.6122.24 ± 0.935
SecondaryAlanine Aminotransferase: Week 12

The observed values of alanine aminotransferase at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · units per liter (U/L)
Alanine Aminotransferase: Week 12
units per liter (U/L)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Alanine Aminotransferase: Week 1212.1 ± 6.6118.6 ± 13.8519.9 ± 10.8919.0 ± 9.43
SecondaryAlanine Aminotransferase: Week 24

The observed values of alanine aminotransferase at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · U/L
Alanine Aminotransferase: Week 24
U/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Alanine Aminotransferase: Week 248.7 ± 4.6711.9 ± 4.7815.3 ± 6.8115.4 ± 6.35
SecondaryAlbumin: Week 12

The observed values of albumin at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · g/dL
Albumin: Week 12
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Albumin: Week 123.96 ± 0.3823.90 ± 0.2103.97 ± 0.3043.98 ± 0.273
SecondaryAlbumin: Week 24

The observed values of albumin at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · g/dL
Albumin: Week 24
g/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Albumin: Week 243.75 ± 0.4323.83 ± 0.3053.77 ± 0.3473.84 ± 0.456
SecondaryAlkaline Phosphatase: Week 12

The observed values of alkaline phosphatase at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · U/L
Alkaline Phosphatase: Week 12
U/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Alkaline Phosphatase: Week 12103.0 ± 56.43125.4 ± 87.32107.5 ± 57.54106.2 ± 44.69
SecondaryAlkaline Phosphatase: Week 24

The observed values of alkaline phosphatase at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · U/L
Alkaline Phosphatase: Week 24
U/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Alkaline Phosphatase: Week 2499.8 ± 51.17140.6 ± 119.26121.2 ± 55.2695.2 ± 53.01
SecondaryAspartate Aminotransferase: Week 12

The observed values of aspartate aminotransferase at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · U/L
Aspartate Aminotransferase: Week 12
U/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Aspartate Aminotransferase: Week 1215.5 ± 5.8918.1 ± 11.5720.5 ± 10.8515.7 ± 4.61
SecondaryAspartate Aminotransferase: Week 24

The observed values of aspartate aminotransferase at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · U/L
Aspartate Aminotransferase: Week 24
U/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Aspartate Aminotransferase: Week 2414.7 ± 5.5714.3 ± 5.5917.3 ± 7.7514.7 ± 3.20
SecondaryBicarbonate: Week 12

The observed values of bicarbonate at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · millimoles per liter (mmol/L)
Bicarbonate: Week 12
millimoles per liter (mmol/L)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Bicarbonate: Week 1223.5 ± 3.0623.1 ± 3.0322.7 ± 3.2625.5 ± 3.50
SecondaryBicarbonate: Week 24

The observed values of bicarbonate at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mmol/L
Bicarbonate: Week 24
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Bicarbonate: Week 2423.3 ± 3.0024.6 ± 2.8322.4 ± 2.4326.0 ± 3.28
SecondaryBilirubin: Week 12

The observed values of bilirubin at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Bilirubin: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Bilirubin: Week 120.490 ± 0.1860.450 ± 0.1570.603 ± 0.2340.553 ± 0.150
SecondaryBilirubin: Week 24

The observed values of bilirubin at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Bilirubin: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Bilirubin: Week 240.450 ± 0.1690.430 ± 0.1420.565 ± 0.1840.520 ± 0.125
SecondaryCalcium: Week 12

The observed values of calcium at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Calcium: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Calcium: Week 128.89 ± 0.8838.54 ± 0.7378.90 ± 0.7778.39 ± 0.727
SecondaryCalcium: Week 24

The observed values of calcium at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Calcium: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Calcium: Week 248.73 ± 0.7408.95 ± 0.7348.76 ± 0.6538.82 ± 1.011
SecondaryChloride: Week 12

The observed values of chloride at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mmol/L
Chloride: Week 12
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Chloride: Week 1297.0 ± 3.6998.6 ± 5.3498.0 ± 4.8798.5 ± 2.47
SecondaryChloride: Week 24

The observed values of chloride at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mmol/L
Chloride: Week 24
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Chloride: Week 2498.5 ± 3.6797.7 ± 4.7698.7 ± 3.1597.6 ± 3.73
SecondaryCholesterol: Week 12

The observed values of cholesterol at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Cholesterol: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Cholesterol: Week 12140.4 ± 41.24140.3 ± 40.51145.9 ± 41.38146.0 ± 43.54
SecondaryCholesterol: Week 24

The observed values of cholesterol at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Cholesterol: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Cholesterol: Week 24130.5 ± 40.19148.3 ± 38.74131.2 ± 36.17158.0 ± 44.04
SecondaryCreatinine: Week 12

The observed values of creatinine at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Creatinine: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Creatinine: Week 129.458 ± 2.7399.616 ± 2.6429.227 ± 2.52610.115 ± 3.391
SecondaryCreatinine: Week 24

The observed values of creatinine at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Creatinine: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Creatinine: Week 249.086 ± 2.2609.173 ± 2.5419.027 ± 2.2169.703 ± 3.714
SecondaryDirect Bilirubin: Week 12

The observed values of direct bilirubin at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Direct Bilirubin: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Direct Bilirubin: Week 120.101 ± 0.0710.098 ± 0.0660.123 ± 0.0490.118 ± 0.059
SecondaryDirect Bilirubin: Week 24

The observed values of direct bilirubin at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Direct Bilirubin: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Direct Bilirubin: Week 240.105 ± 0.0810.081 ± 0.0460.124 ± 0.0530.102 ± 0.042
SecondaryGlucose: Week 12

The observed values of glucose at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Glucose: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Glucose: Week 12123.1 ± 52.29128.5 ± 66.17119.6 ± 73.49101.2 ± 19.86
SecondaryGlucose: Week 24

The observed values of glucose at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Glucose: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Glucose: Week 24129.5 ± 54.83129.9 ± 64.12142.4 ± 168.55104.2 ± 22.97
SecondaryHigh-density Lipoprotein (HDL) Cholesterol: Week 12

The observed values of HDL cholesterol at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
High-density Lipoprotein (HDL) Cholesterol: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
High-density Lipoprotein (HDL) Cholesterol: Week 1251.6 ± 16.4750.1 ± 18.0554.2 ± 17.1752.5 ± 15.14
SecondaryHDL Cholesterol: Week 24

The observed values of HDL cholesterol at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
HDL Cholesterol: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
HDL Cholesterol: Week 2450.5 ± 17.3345.4 ± 16.0248.8 ± 16.2946.8 ± 22.49
SecondaryHepcidin-25: Week 12

The observed values of hepcidin-25 at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · nanogram/milliliter (ng/mL)
Hepcidin-25: Week 12
nanogram/milliliter (ng/mL)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hepcidin-25: Week 12310.67 ± 163.569344.99 ± 154.189288.72 ± 210.049233.89 ± 114.748
SecondaryHepcidin-25: Week 24

The observed values of hepcidin-25 at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · ng/mL
Hepcidin-25: Week 24
ng/mLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Hepcidin-25: Week 24347.55 ± 167.752328.35 ± 159.543302.72 ± 131.966262.18 ± 118.461
SecondaryLow-density Lipoproteins (LDL) Cholesterol: Week 12

The observed values of LDL cholesterol at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Low-density Lipoproteins (LDL) Cholesterol: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Low-density Lipoproteins (LDL) Cholesterol: Week 1267.2 ± 29.6261.4 ± 31.4063.8 ± 32.6968.1 ± 39.58
SecondaryLDL Cholesterol: Week 24

The observed values of LDL cholesterol at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
LDL Cholesterol: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
LDL Cholesterol: Week 2460.9 ± 32.5969.4 ± 30.4454.7 ± 27.7382.7 ± 35.43
SecondaryLipoprotein-a: Week 12

The observed values of lipoprotein-a at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Nanomoles per litre (nmol/L)
Lipoprotein-a: Week 12
Nanomoles per litre (nmol/L)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lipoprotein-a: Week 1235.2 ± 38.8886.3 ± 83.2968.9 ± 50.1153.1 ± 41.54
SecondaryLipoprotein-a: Week 24

The observed values of lipoprotein-a at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · nmol/L
Lipoprotein-a: Week 24
nmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Lipoprotein-a: Week 2439.3 ± 37.6096.6 ± 92.5289.5 ± 61.2561.9 ± 52.28
SecondaryPhosphate: Week 12

The observed values of phosphate at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Phosphate: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Phosphate: Week 125.06 ± 1.4255.67 ± 1.9056.51 ± 1.3645.43 ± 1.416
SecondaryPhosphate: Week 24

The observed values of phosphate at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Phosphate: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Phosphate: Week 245.55 ± 1.8414.57 ± 1.3995.15 ± 0.7245.64 ± 1.459
SecondaryPotassium: Week 12

The observed values of potassium at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mmol/L
Potassium: Week 12
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Potassium: Week 125.13 ± 1.0945.06 ± 0.7545.03 ± 0.6624.69 ± 0.647
SecondaryPotassium: Week 24

The observed values of potassium at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mmol/L
Potassium: Week 24
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Potassium: Week 244.96 ± 0.6284.97 ± 0.5814.71 ± 0.4664.75 ± 0.762
SecondarySodium: Week 12

The observed values of sodium at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mmol/L
Sodium: Week 12
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Sodium: Week 12135.8 ± 2.80137.1 ± 4.55137.4 ± 4.03138.6 ± 3.64
SecondarySodium: Week 24

The observed values of sodium at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mmol/L
Sodium: Week 24
mmol/LPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Sodium: Week 24136.7 ± 3.04136.2 ± 4.90137.8 ± 4.24137.2 ± 4.06
SecondaryTriglycerides: Week 12

The observed values of triglyceride at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Triglycerides: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Triglycerides: Week 12107.9 ± 50.59140.8 ± 131.19139.5 ± 85.00126.7 ± 89.04
SecondaryTriglycerides: Week 24

The observed values of triglycerides at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Triglycerides: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Triglycerides: Week 2495.4 ± 53.98166.9 ± 120.39146.6 ± 147.52142.9 ± 95.94
SecondaryUrea Nitrogen: Week 12

The observed values of urea nitrogen at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mg/dL
Urea Nitrogen: Week 12
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Urea Nitrogen: Week 1261.7 ± 26.0361.1 ± 17.4053.3 ± 12.3862.1 ± 21.06
SecondaryUrea Nitrogen: Week 24

The observed values of urea nitrogen at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mg/dL
Urea Nitrogen: Week 24
mg/dLPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Urea Nitrogen: Week 2466.2 ± 30.0459.9 ± 16.9751.1 ± 13.6759.6 ± 15.11
SecondaryPre-dialysis Body Mass Index (BMI): Week 12

Pre-dialysis BMI values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · kilogram per meter^2 (kg/m^2)
Pre-dialysis Body Mass Index (BMI): Week 12
kilogram per meter^2 (kg/m^2)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Body Mass Index (BMI): Week 1228.952 ± 5.77429.668 ± 8.67432.150 ± 9.36532.574 ± 8.240
SecondaryPre-infusion BMI: Week 11

Pre-infusion BMI values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · Kg/m^2
Pre-infusion BMI: Week 11
Kg/m^2PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion BMI: Week 1129.337 ± 6.80029.399 ± 8.26731.290 ± 8.34134.163 ± 7.950
SecondaryPre-dialysis Diastolic Blood Pressure: Week 12

Pre-dialysis diastolic blood pressure values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Millimetre of mercury (mm Hg)
Pre-dialysis Diastolic Blood Pressure: Week 12
Millimetre of mercury (mm Hg)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Diastolic Blood Pressure: Week 1284.8 ± 21.1470.4 ± 11.7084.2 ± 10.2376.3 ± 16.29
SecondaryPre-dialysis Diastolic Blood Pressure: Week 24

Pre-dialysis diastolic blood pressure values at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mm Hg
Pre-dialysis Diastolic Blood Pressure: Week 24
mm HgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Diastolic Blood Pressure: Week 2476.9 ± 13.5977.8 ± 13.2374.0 ± 14.5378.8 ± 13.74
SecondaryPre-infusion Diastolic Blood Pressure: Week 11

Pre-infusion diastolic blood pressure values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · mm Hg
Pre-infusion Diastolic Blood Pressure: Week 11
mm HgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Diastolic Blood Pressure: Week 1182.3 ± 19.6866.6 ± 10.0375.8 ± 11.8078.7 ± 10.71
SecondaryPre-dialysis Heart Rate: Week 12

Pre-dialysis heart rate values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · beats/min
Pre-dialysis Heart Rate: Week 12
beats/minPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Heart Rate: Week 1269.3 ± 7.5071.1 ± 12.2070.8 ± 8.0376.9 ± 13.37
SecondaryPre-dialysis Heart Rate: Week 24

Pre-dialysis heart rate values at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · beats/min
Pre-dialysis Heart Rate: Week 24
beats/minPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Heart Rate: Week 2471.8 ± 12.0278.0 ± 11.9072.6 ± 10.0378.9 ± 17.72
SecondaryPre-infusion Heart Rate: Week 11

Pre-infusion heart rate values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · beats/min
Pre-infusion Heart Rate: Week 11
beats/minPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Heart Rate: Week 1167.1 ± 6.1170.1 ± 9.4465.7 ± 8.8872.8 ± 9.80
SecondaryPre-dialysis Respiration Rate: Week 12

Pre-dialysis respiration rate values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · breaths per minute (breaths/min)
Pre-dialysis Respiration Rate: Week 12
breaths per minute (breaths/min)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Respiration Rate: Week 1217.8 ± 1.2717.9 ± 1.2917.9 ± 1.5318.1 ± 1.31
SecondaryPre-dialysis Respiration Rate: Week 24

Pre-dialysis respiration rate values at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · breaths/min
Pre-dialysis Respiration Rate: Week 24
breaths/minPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Respiration Rate: Week 2416.6 ± 2.6918.1 ± 1.0918.3 ± 1.6018.4 ± 1.08
SecondaryPre-infusion Respiration Rate: Week 11

Pre-infusion respiration rate values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · breaths/min
Pre-infusion Respiration Rate: Week 11
breaths/minPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Respiration Rate: Week 1118.1 ± 1.2217.8 ± 1.2418.1 ± 1.3918.3 ± 1.23
SecondaryPre-dialysis Systolic Blood Pressure: Week 12

Pre-dialysis values of systolic blood pressure at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · mm Hg
Pre-dialysis Systolic Blood Pressure: Week 12
mm HgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Systolic Blood Pressure: Week 12164.4 ± 33.13143.8 ± 21.04164.3 ± 25.17151.4 ± 26.83
SecondaryPre-dialysis Systolic Blood Pressure: Week 24

Pre-dialysis values of systolic blood pressure at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · mm Hg
Pre-dialysis Systolic Blood Pressure: Week 24
mm HgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Systolic Blood Pressure: Week 24149.4 ± 30.43146.7 ± 19.14157.6 ± 27.45155.8 ± 22.93
SecondaryPre-infusion Systolic Blood Pressure: Week 11

Pre-infusion systolic blood pressure values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · mm Hg
Pre-infusion Systolic Blood Pressure: Week 11
mm HgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Systolic Blood Pressure: Week 11161.2 ± 25.78138.7 ± 27.32144.0 ± 28.30152.1 ± 28.18
SecondaryPre-dialysis Weight: Week 12

Pre-dialysis weight values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Kilogram (Kg)
Pre-dialysis Weight: Week 12
Kilogram (Kg)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Weight: Week 1284.583 ± 18.46482.162 ± 28.83092.120 ± 25.72096.213 ± 29.206
SecondaryPre-infusion Weight: Week 11

Pre-infusion weight values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · Kg
Pre-infusion Weight: Week 11
KgPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Weight: Week 1186.356 ± 21.88183.433 ± 31.58092.043 ± 26.40191.217 ± 15.121
SecondaryPre-dialysis Temperature: Week 12

Pre-dialysis temperature values at week 12 are presented.

Time frame:
At week 12
Reported as:
Mean · Celsius (C)
Pre-dialysis Temperature: Week 12
Celsius (C)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Temperature: Week 1236.259 ± 0.57236.435 ± 0.30436.436 ± 0.31436.490 ± 0.157
SecondaryPre-dialysis Temperature: Week 24

Pre-dialysis temperature values at week 24 are presented.

Time frame:
At week 24
Reported as:
Mean · C
Pre-dialysis Temperature: Week 24
CPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-dialysis Temperature: Week 2436.328 ± 0.38436.440 ± 0.31536.168 ± 0.37036.361 ± 0.251
SecondaryPre-infusion Temperature: Week 11

Pre-infusion temperature values at week 11 are presented.

Time frame:
At week 11
Reported as:
Mean · C
Pre-infusion Temperature: Week 11
CPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Pre-infusion Temperature: Week 1136.182 ± 0.69236.377 ± 0.25936.187 ± 0.49436.375 ± 0.193
SecondaryArea Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-001

Area under the serum concentration time curve from time 0 to infinity (AUC 0-α) of COR-001 is presented.

Time frame:
Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Reported as:
Mean · nanogram*day/milliliter (ng*day/mL)
Area Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-001
nanogram*day/milliliter (ng*day/mL)COR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Area Under the Serum Concentration Time Curve From Time 0 to Infinity (AUC 0-α) of COR-00111962 ± 473140911 ± 23629118177 ± 60393
SecondaryElimination Half-life in the Initial Phase (t 1/2,α)

Elimination half-life in the initial phase (t 1/2,α) is presented from week 0 to week 35.

Time frame:
Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Reported as:
Mean · Days
Elimination Half-life in the Initial Phase (t 1/2,α)
DaysCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Elimination Half-life in the Initial Phase (t 1/2,α)2.55 ± 0.941.98 ± 0.871.90 ± 0.70
SecondaryElimination Half-life in the Terminal Phase (t 1/2, z)

Elimination half-life in the terminal phase(t 1/2, z) is presented from week 0 to week 35.

Time frame:
Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Reported as:
Mean · Days
Elimination Half-life in the Terminal Phase (t 1/2, z)
DaysCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Elimination Half-life in the Terminal Phase (t 1/2, z)51.44 ± 21.5538.22 ± 14.2140.93 ± 13.43
SecondaryMaximum Serum Concentration (Cmax)

Maximum serum concentration (Cmax) of COR-001 from week 0 to week 35 is presented.

Time frame:
Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Reported as:
Mean · ng/mL
Maximum Serum Concentration (Cmax)
ng/mLCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Maximum Serum Concentration (Cmax)378 ± 931368 ± 3593584 ± 1349
SecondaryImpact of ADAs on Pharmacokinetics

Presence of ADA was a covariate for pharmacokinetics (PK) affecting V1 (volume of distribution for the central compartment). Impact of ADAs on V1 from baseline to week 35 is presented. In the below table, result presented is the bootstrap parameter estimate of the effect of ADA on V1 for a PK model that includes data for all arms combined.

Time frame:
Week 1 (day 1, 3, and 5), Week 2 (day 8), Week 3 (day 15), Week 5 (day 29), Week 7 (day 43), Week 8 (day 50), Week 9 (day 57), Week 11 (day 71 and 75), Week 14 (day 92), Week 18 (day 120) and Week 35 (day 239).
Reported as:
Mean · Milliliter (mL)
Impact of ADAs on Pharmacokinetics
Milliliter (mL)COR-001
Impact of ADAs on Pharmacokinetics0.361 (0.0548 to 0.658)

Adverse events

Collected over Weeks 0-24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/12 (0%)3/12 (25%)7/12 (58.3%)
COR-001 2 mg0/16 (0%)4/16 (25%)11/16 (68.8%)
COR-001 6 mg2/16 (12.5%)7/16 (43.8%)15/16 (93.8%)
COR-001 20 mg2/17 (11.8%)6/17 (35.3%)10/17 (58.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
Cardiac failure congestiveCardiac disorders0/120/164/160/17
Hypertensive emergencyVascular disorders2/120/161/160/17
Fluid overloadMetabolism and nutrition disorders0/120/162/160/17
Arteriovenous fistula site complicationInjury, poisoning and procedural complications1/120/160/160/17
Arteriovenous fistula site infectionInfections and infestations1/120/160/160/17
EncephalopathyNervous system disorders1/120/160/160/17
HypertensionVascular disorders1/120/160/160/17
Osteomyelitis acuteInfections and infestations1/120/160/160/17
AnaemiaBlood and lymphatic system disorders0/120/161/160/17
Appendicitis perforatedInfections and infestations0/121/160/160/17
Most frequent other events
Showing 10 of 125
Most frequent other events
EventPlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mg
DyspnoeaRespiratory, thoracic and mediastinal disorders1/120/164/161/17
HypoglycaemiaMetabolism and nutrition disorders0/122/163/160/17
VomitingGastrointestinal disorders1/123/161/160/17
HyperparathyroidismEndocrine disorders2/120/160/160/17
Pain in extremityMusculoskeletal and connective tissue disorders2/121/161/161/17
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/120/162/160/17
HyperkalaemiaMetabolism and nutrition disorders0/122/162/160/17
HypertensionVascular disorders0/120/162/161/17
HyponatraemiaMetabolism and nutrition disorders0/120/162/161/17
ArthralgiaMusculoskeletal and connective tissue disorders0/120/160/162/17

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(Years)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mgTotal
Mean62.8 ± 10.2361.4 ± 12.9563.8 ± 10.9857.9 ± 10.5661.3 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mgTotal
Female398929
Male978832
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mgTotal
Hispanic or Latino673420
Not Hispanic or Latino69131341
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCOR-001 2 mgCOR-001 6 mgCOR-001 20 mgTotal
American Indian or Alaska Native00000
Asian01214
Native Hawaiian or Other Pacific Islander00000
Black or African American55101131
White7104526
More than one race00000
Unknown or Not Reported00000
08

Study locations

12 sites
  • Novo Nordisk Investigational Site
    Northridge, California 91324, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33025, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33614, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30909, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60643, United States
  • Novo Nordisk Investigational Site
    North Brunswick, New Jersey 08902, United States
  • Novo Nordisk Investigational Site
    Astoria, New York 11102, United States
  • Novo Nordisk Investigational Site
    Fresh Meadows, New York 11365, United States
  • Novo Nordisk Investigational Site
    Great Neck, New York 11021, United States
  • Novo Nordisk Investigational Site
    Providence, Rhode Island 02915, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77099, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
09

References and documents

Publications

  • Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 Jan;32(1):211-222. doi: 10.1681/ASN.2020050595. Epub 2020 Dec 3. PubMed 33272965 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Dec 2018, 26 months.

Results were first posted in Jul 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2016
First posted
Aug 16, 2016
StartActual
Sep 12, 2016
Primary completionActual
Dec 11, 2018
CompletionActual
Dec 11, 2018
Results delay requested
Jan 18, 2021
Results first posted
Jul 30, 2021
Last update
Jul 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02868229
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Sep 12, 2016
Primary completion
Dec 11, 2018
Completion
Dec 11, 2018
Results posted
Jul 30, 2021
Last update
Jul 30, 2021

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion